Your browser doesn't support javascript.
loading
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
Funk, Patrick R; Yogurtcu, Osman N; Forshee, Richard A; Anderson, Steve A; Marks, Peter W; Yang, Hong.
Afiliação
  • Funk PR; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
  • Yogurtcu ON; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
  • Forshee RA; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
  • Anderson SA; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
  • Marks PW; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA; Office of the Center Director, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
  • Yang H; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA. Electronic address: Hong.Yang@fda.hhs.gov.
Vaccine ; 40(19): 2781-2789, 2022 04 26.
Article em En | MEDLINE | ID: mdl-35370016
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pericardite / COVID-19 / Miocardite Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pericardite / COVID-19 / Miocardite Idioma: En Ano de publicação: 2022 Tipo de documento: Article